Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model

Bone Marrow Transplantation volume 42, pages S25–S30 (2008)Cite this article

Abstract

New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78 neuroblastoma patients reported to the European Group for Blood and Marrow Transplantation activity survey from 2002 to 2007 and less than 100 published cases. Two trends can be observed in the reviewed data: some teams have used allo-HSCT in children with refractory or progressive disease and significant tumor burden and other teams in children with CR, PR or minimal residual disease earlier in their disease process. Early studies of allo-HSCT in children with high-risk neuroblastoma suggest that this is a feasible approach that may improve outcome in this deadly disease. However, the proper timing for allo-HSCT during the disease course remains to be determined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Maris JM, Hogarty MD, Bagatell R, Cohn SL . Neuroblastoma. Lancet 2007; 369: 2106–2120.

    Article  CAS  Google Scholar 

  2. Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A, for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 2004; 34: 855–875.

    Article  CAS  Google Scholar 

  3. Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R et al. Hematopoetic stem cell transplantation for solid tumors in Europe. Ann Oncol 2004; 15: 653–660.

    Article  CAS  Google Scholar 

  4. Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urbano-Ispizua A, for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE). Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant 2005; 36: 575–590.

    Article  CAS  Google Scholar 

  5. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A . EBMT Activity survey 2004 and changes in disease indication over the last 15 years. Bone Marrow Transplant 2006; 37: 1069–1085.

    Article  CAS  Google Scholar 

  6. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D, for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE). Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71–87.

    Article  CAS  Google Scholar 

  7. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D, for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE). The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008; 41: 687–705.

    Article  CAS  Google Scholar 

  8. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al., for the European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439–449.

    Article  CAS  Google Scholar 

  9. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O’Leary MC, Harris RE et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 2382–2389.

    Article  CAS  Google Scholar 

  10. Ladenstein R, Lasset C, Hartmann O, Klingebiel T, Bouffet E, Gadner H et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 37–46.

    CAS  PubMed  Google Scholar 

  11. Inoue M, Okamura T, Yasui M, Sawada A, Sakata N, Koyama M et al. Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children. Bone Marrow Transplant 2006; 37: 601–605.

    Article  CAS  Google Scholar 

  12. Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002; 100: 2554–2561.

    Article  CAS  Google Scholar 

  13. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101: 1718–1726.

    Article  CAS  Google Scholar 

  14. Hirayama M, Azuma E, Araki M, Komada Y, Nakagawa A . Evidence of Graft-versus-Tumor Effect in Refractory Metastatic Neuroblastoma. Transplantation 2006; 82: 142–143.

    Article  Google Scholar 

  15. Marabelle A, Paillard C, Tchirkov A, Halle P, Chassagne J, Demeocq F et al. Graft-versus-tumour effect in refractory metastatic neuroblastoma. Bone Marrow Transplant 2007; 39: 809–810.

    Article  CAS  Google Scholar 

  16. Del Toro G, Satwani P, Harrison L, Cheung Y-K, Erigid Bradley M, George D et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613–622.

    Article  CAS  Google Scholar 

  17. Del Toro GD, Bradley M, Satwani P, Morris E, Ven Cvd, Cheung YK et al. Reduced intensity (RI) allogeneic cord blood hematopoietic cell transplantation (Allo CBHCT) in pediatric patients with malignant and non-malignant diseases. Biol Blood Marrow Transplant 2006; 12: 125.

    Article  Google Scholar 

  18. Yamashiro DJ, Lee A, Bhatia M, Glade-Bender J, Qualter E, Militano O et al. Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma: a single institution pilot study. Biol Blood Marrow Transplant 2007; 13: 68–69.

    Article  Google Scholar 

  19. Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006; 218: 321–326.

    Article  CAS  Google Scholar 

  20. Inoue M, Nakano T, Yoneda A, Nishikawa M, Nakayama M, Yumura-Yagi K et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haploidentical bone marrow transplantation. Bone Marrow Transplant 2003; 32: 103–106.

    Article  CAS  Google Scholar 

  21. Takahashi H, Manabe A, Aoyama C, Kamiya T, Kato I, Takusagawa A et al. Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma. Pediatr Blood Cancer 2008; 50: 676–678.

    Article  Google Scholar 

  22. Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 2003; 75: 2135–2143.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The cooperation of all participating teams and their staff, the EBMT Co-ordination office; Barcelona (F McDonald, E McGrath, SM Jones, EJ Mac Hale), Paris (V Chesnel, C Kenzey, C Durand, NC Gorin), London (C Ruiz de Elvira, S Hewerdine, S de Souza, N Fortin-Robertson), the Austrian Registry (H Greinix, B Lindner), the Czech Registry (K Benesova, M Trnkova), the French Registry SFGM (D Blaise, C Raffoux, Z Chir), the German Registry (H Ottinger, K Fuchs, C Müller, S Allgaier, A Müller), the Italian Registry (A Bacigalupo, R Oneto, B Bruno), the Dutch Registry (A Schattenberg, Av Biezen, M Sneets, R Brand), the Spanish Registry (J. Rifon, A Cedillo, J López), the Swiss Registry (U Schanz, H Baldomero, E Buhrfeind), the Turkish Registry (G Gurman, M Arat, F Arpaci, M Ertem) and the British Registry (C Craddock, J Cornish, K Towlson, M Wilson) is greatly appreciated. The Activity survey was supported in part by the European Leukemia Net LSH-2002-2.2.0-3, by a grant from the Swiss National Research Foundation, 3200B0-118176 the Swiss Cancer League, the Regional Cancer League and the Horton Foundation. EBMT is supported by grants from the corporate members: Amgen Europe GmbH, F. Hoffmann-La Roche Ltd, Gilead Sciences UK, Miltenyl Biotec GmbH, Schering-Plough International Inc., Celegene International SARL, Genzyme, Chugai sanofi—aventis SNC, Fresenius Biotech GmbH, Gambro BCT, Bayer Schering Pharma AG, Therakos, Bristol Myers Squibb, Novartis, Pharmacon, Cephalon, Pierre Fabre Médicament, GE Healthcare, Alexion Europe, Pfizer, Biosafe SA., Merck Sharp and Dohme.

Author information

Authors and Affiliations

  1. Centre Hospitalier et Universitaire de Clermont-Ferrand, Service de Pédiatrie B et Unité Bioclinique de Thérapie Cellulaire, Clermont-Ferrand, France

    J Kanold, C Paillard, E Merlin, A Marabelle & F Deméocq

  2. Faculté de Médecine, Université Clermont 1, Clermont-Ferrand, France

    J Kanold, A Tchirkov, E Merlin & F Deméocq

  3. INSERM, CIC501, Clermont-Ferrand, France

    J Kanold, C Paillard, E Merlin & F Deméocq

  4. Service de Cytogénétique Médicale, Faculté de Médecine, Université Clermont 1, Clermont-Ferrand, France

    A Tchirkov

  5. IHOP Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Leon Berard, Lyon, France

    A Marabelle & R Rousseau

  6. Service de Pédiatrie I, Hôpital Civil, Strasbourg, France

    P Lutz

  7. Department of Medicine, EBMT Transplant Activity Survey Office, University Hospital Basel, Basel, Switzerland

    H Baldomero

Authors
  1. J Kanold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Paillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Tchirkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Merlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Marabelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Rousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Baldomero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Deméocq
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Kanold.

Additional information

Conflict of interest

The authors have declared no financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanold, J., Paillard, C., Tchirkov, A. et al. Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model. Bone Marrow Transplant 42 (Suppl 2), S25–S30 (2008). https://doi.org/10.1038/bmt.2008.279

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.279

Keywords

This article is cited by

Search

Advanced search

Quick links